The DOI matches its Crossref record.
Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency
Abstract
BACKGROUND: Chronic renal insufficiency is accompanied by specific alterations of the lipoprotein metabolism. It has been suggested that the renal dyslipoproteinaemia of renal insufficiency contributes to the progression of glomerular and tubular lesions, with subsequent deterioration of renal function. The objective of this prospective study was to investigate whether the specific lipoprotein abnormalities of renal insufficiency are associated with the rate of decline of renal function in patients with moderately advanced chronic renal failure. METHODS: A patient population of 73 adult non-diabetic patients with primary chronic renal disease were followed with repeated measurements of the glomerular filtration rate (GFR) for an average of 3.2 (SD 0.7) years. Forty-three of these patients had chronic glomerulonephritis as the underlying renal disease. Patient characteristics including plasma levels of lipids and apolipoproteins were determined at entry and were prospectively related, using linear regression, to the rate of progression. RESULTS: The mean GFR at entry was 41.3 (SD 15.3) ml/min x 1.73 m2 BSA. The average rate of progression was a decline in GFR of -2.8 (SD 3.7) ml/min x 1.73 m2 BSA per year. In the whole patient study group total cholesterol, low-density lipoprotein (LDL) cholesterol, and apolipoprotein B (apoB) were all significantly associated with a more rapid decline in renal function, whereas triglycerides, high-density lipoprotein (HDL) cholesterol, and apolipoprotein A (apoA) were not. In the more homogeneous subgroup of patients with chronic glomerulonephritis the association between dyslipidaemia and the rate of progression was even more pronounced. In this subgroup of patients also serum triglycerides and apoE were significantly associated with a higher rate of progression. Both the initial blood pressure and proteinuria were also significantly associated with a more rapid decline in renal function in the whole study group as well as in patients with chronic glomerulonephritis. The associations between these variables with the rate of progression were all independent of the entry GFR values. CONCLUSIONS: These results indicate that the lipoprotein abnormalities of renal insufficiency contribute to the progression of renal failure in human chronic renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Predictors of New-Onset Kidney Disease in a Community-Based Population
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.291.7.844 · Cited by 1,241
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00165.x · Cited by 667
Cardiovascular disease and chronic renal disease: A new paradigm
Sarnak, M. J., & Levey, A. S. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70239-3 · Cited by 586
Progression, remission, regression of chronic renal diseases
Ruggenenti, P., Schieppati, A., & Remuzzi, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04728-0 · Cited by 554
Statins for Improving Renal Outcomes: A Meta-Analysis
Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010012 · Cited by 478
Cholesterol and the risk of renal dysfunction in apparently healthy men
Schaeffner, E. S., Kurth, T., Curhan, G. C., Glynn, R. J., Rexrode, K. M., Baigent, C., Buring, J. E., & Gaziano, J. M. (2003) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1482084 · Cited by 442
Bianchi, S., Bigazzi, R., Caiazza, A., & Campese, V. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50140 · Cited by 332
Kasiske, B., Cosio, F. G., Beto, J., Bolton, K., Chavers, B. M., Grimm, R., Levin, A., Masri, B., Parekh, R., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 316
Bonnet, F., Deprele, C., Sassolas, A., Moulin, P., alamartine, E., Berthezène, F., & Berthoux, F. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80120-7 · Cited by 311
Predicting initiation and progression of chronic kidney disease: Developing renal risk scores
Taal, M. W., & Brenner, B. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001794 · Cited by 282
Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease
Abrass, C. K. (2004) · American Journal of Nephrology · doi:10.1159/000075925 · Cited by 279
Chronic Renal Diseases: Renoprotective Benefits of Renin–Angiotensin System Inhibition
Remuzzi, G., Ruggenenti, P., & Perico, N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-8-200204160-00010 · Cited by 272
Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy
Syrjänen, J., Mustonen, J., & Pasternack, A. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.1.34 · Cited by 257
Metadata
- Authors
- Samuelsson, O., Mulec, H., Knight-Gibson, C., Attman, P., Kron, B., Larrson, R., Weiss, L., Wedel, H., & Alaupovic, P.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-09-01
- Volume
- 12
- Issue
- 9
- Pages
- 1908-1915
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2155019824
- Cited by
- 234
- References
- 0
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.